3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
8
Prostatic Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
HER2-positive Breast Cancer
2
Endometrial Neoplasms
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Melanoma
1
Malignant Solid Neoplasm
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
HR+/HER2+ Early Breast Cancer
1
Glioma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
fludarabine
10
Specimen Handling
8
Cytarabine
8
Cyclophosphamide
8
Biopsy
8
fludarabine phosphate
7
Whole-Body Irradiation
7
venetoclax
6
Injections
6
Busulfan
6
Azacitidine
6
Mycophenolic Acid
5
Melphalan
5
Granulocyte Colony-Stimulating Factor
5
Filgrastim
5
decitabine and cedazuridine drug combination
4
X-Rays
4
Tacrolimus
4
Stem Cell Transplantation
4
Cyclosporine
4
CPX-351
4
Peripheral Blood Stem Cell Transplantation
3
Magnetic Resonance Spectroscopy
3
Idarubicin
3
Decitabine
3
treosulfan
2
ruxolitinib
2
luspatercept
2
ivosidenib
2
gilteritinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myelodysplastic Syndromes
×
pertuzumab
×
30 days
×
Clear all
No trials found.